These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8821687)

  • 21. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
    Guay DR
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
    Roehrborn CG
    Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Roehrborn CG
    Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Elhilali MM
    Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
    Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfuzosin for the management of benign prostate hyperplasia.
    Weiner DM; Lowe FC
    Expert Opin Pharmacother; 2003 Nov; 4(11):2057-63. PubMed ID: 14596659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
    Hartung R; Matzkin H; Alcaraz A; Emberton M; Harving N; van Moorselaar J; Elhilali M; Vallancien G;
    J Urol; 2006 Feb; 175(2):624-8; discussion 628. PubMed ID: 16407011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.